Refractory primary immune thrombocytopenia (ITP): current clinical challenges and therapeutic perspectives

Chronic primary immune thrombocytopenia (ITP) can today benefit from multiple therapeutic approaches with proven clinical efficacy, including rituximab, thrombopoietin receptor agonists (TPO-RA), and splenectomy. However, some ITP patients are unresponsive to multiple lines of therapy with prolonged...

Descripción completa

Detalles Bibliográficos
Autores principales: Vianelli, Nicola, Auteri, Giuseppe, Buccisano, Francesco, Carrai, Valentina, Baldacci, Erminia, Clissa, Cristina, Bartoletti, Daniela, Giuffrida, Gaetano, Magro, Domenico, Rivolti, Elena, Esposito, Daniela, Podda, Gian Marco, Palandri, Francesca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8867457/
https://www.ncbi.nlm.nih.gov/pubmed/35201417
http://dx.doi.org/10.1007/s00277-022-04786-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8867457/
https://www.ncbi.nlm.nih.gov/pubmed/35201417
http://dx.doi.org/10.1007/s00277-022-04786-y

Ejemplares similares